| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David R Andes | |
| Jeniel E Nett | |||
| P2860 | cites work | Biofilms: survival mechanisms of clinically relevant microorganisms | Q22299328 |
| Secreted Proteases Control Autolysin-mediated Biofilm Growth of Staphylococcus aureus | Q27679788 | ||
| Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms | Q28302942 | ||
| Hsp90 governs dispersion and drug resistance of fungal biofilms | Q28476836 | ||
| A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance | Q28481813 | ||
| The Extracellular Matrix of Candida albicans Biofilms Impairs Formation of Neutrophil Extracellular Traps | Q28554057 | ||
| The biofilm matrix | Q29547334 | ||
| Novel cell death program leads to neutrophil extracellular traps | Q29615433 | ||
| Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 | ||
| Candida biofilms: an update | Q30475833 | ||
| Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines | Q30479433 | ||
| Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance | Q30701532 | ||
| Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces | Q30799502 | ||
| Characteristics of biofilm formation by Candida albicans. | Q31122279 | ||
| Proteomic analysis of cytoplasmic and surface proteins from yeast cells, hyphae, and biofilms of Candida albicans | Q33422347 | ||
| Biofilm matrix regulation by Candida albicans Zap1. | Q33468384 | ||
| Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. | Q33893698 | ||
| Identification of biofilm matrix-associated proteins from an acid mine drainage microbial community. | Q33936133 | ||
| Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents | Q34024546 | ||
| Novel entries in a fungal biofilm matrix encyclopedia | Q34026267 | ||
| Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene | Q34045325 | ||
| Production of extracellular matrix by Candida albicans biofilms. | Q54144178 | ||
| Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. | Q55689919 | ||
| Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis | Q57181980 | ||
| Candida auris in Healthcare Facilities, New York, USA, 2013-2017 | Q58794314 | ||
| Biofilms of non-Candida albicans Candidaspecies: quantification, structure and matrix composition | Q60483680 | ||
| Conserved Role for Biofilm Matrix Polysaccharides in Drug Resistance | Q60922206 | ||
| Proteomics for the analysis of the Candida albicans biofilm lifestyle | Q79138984 | ||
| Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms | Q82787605 | ||
| Biofilm formation by Candida auris isolated from colonising sites and candidemia cases | Q92315183 | ||
| Fungal β-1,3-glucan increases ofloxacin tolerance of Escherichia coli in a polymicrobial E. coli/Candida albicans biofilm. | Q40676129 | ||
| Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation | Q41838405 | ||
| The bacterial biofilm matrix as a platform for protein delivery | Q42264651 | ||
| Mechanisms involved in the triggering of neutrophil extracellular traps (NETs) by Candida glabrata during planktonic and biofilm growth | Q42376003 | ||
| Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance | Q42545813 | ||
| Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms | Q43415980 | ||
| Attributable mortality of nosocomial candidemia, revisited | Q44386169 | ||
| Effects of interferon-γ and granulocyte colony-stimulating factor on antifungal activity of human polymorphonuclear neutrophils against Candida albicans grown as biofilms or planktonic cells | Q45261277 | ||
| Characteristics of biofilm formation by Candida tropicalis and antifungal resistance | Q46773185 | ||
| Relevance of polymeric matrix enzymes during biofilm formation | Q46785803 | ||
| Macrophage Migration Is Impaired within Candida albicans Biofilms | Q49500207 | ||
| Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. | Q51161653 | ||
| In vitro biofilm formation of Candida albicans and non-albicans Candida species under dynamic and anaerobic conditions. | Q51712735 | ||
| Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. | Q52333026 | ||
| Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. | Q52579452 | ||
| Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. | Q54037537 | ||
| Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection | Q34142971 | ||
| The biofilm matrix--an immobilized but dynamic microbial environment | Q34241209 | ||
| Multistate point-prevalence survey of health care-associated infections | Q34412128 | ||
| Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources | Q34453558 | ||
| Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q34505582 | ||
| Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
| Candida biofilms and their role in infection | Q35044563 | ||
| Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols | Q35164903 | ||
| Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms | Q35218859 | ||
| Community participation in biofilm matrix assembly and function | Q35280502 | ||
| Candida albicans ethanol stimulates Pseudomonas aeruginosa WspR-controlled biofilm formation as part of a cyclic relationship involving phenazines. | Q35360828 | ||
| Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. | Q35598281 | ||
| Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. | Q35635952 | ||
| Polymicrobial interactions: impact on pathogenesis and human disease | Q35666253 | ||
| Biofilm formation by and antifungal susceptibility of Candida isolates from urine | Q35690002 | ||
| An expanded regulatory network temporally controls Candida albicans biofilm formation | Q35732526 | ||
| Candida infections of medical devices | Q35745818 | ||
| Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia | Q35913891 | ||
| Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation | Q35960269 | ||
| Host contributions to construction of three device-associated Candida albicans biofilms | Q36281368 | ||
| Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing | Q36412239 | ||
| Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. | Q36423773 | ||
| Reduced biocide susceptibility in Candida albicans biofilms | Q36870880 | ||
| Our current understanding of fungal biofilms | Q37622959 | ||
| Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms | Q37680035 | ||
| Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. | Q37993043 | ||
| A sticky situation: untangling the transcriptional network controlling biofilm development in Candida albicans | Q38057143 | ||
| The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. | Q38949297 | ||
| Candida albicans biofilms produce antifungal-tolerant persister cells | Q39077924 | ||
| Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. | Q39092336 | ||
| Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy | Q39736606 | ||
| To build a biofilm | Q39750137 | ||
| Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. | Q39767233 | ||
| Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. | Q39932219 | ||
| Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans | Q40335405 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | biofilm | Q467410 |
| P577 | publication date | 2020-02-03 | |
| P1433 | published in | Journal of Fungi | Q27726983 |
| P1476 | title | Contributions of the Biofilm Matrix to Candida Pathogenesis | |
| P478 | volume | 6 |
Search more.